Back to Search
Start Over
Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials.
- Source :
-
Current heart failure reports [Curr Heart Fail Rep] 2024 Aug; Vol. 21 (4), pp. 407-416. Date of Electronic Publication: 2024 May 25. - Publication Year :
- 2024
-
Abstract
- Purpose of Review: End stage kidney disease can be a slow process and it may be challenging to achieve required follow-up for sufficient events. Therefore, a surrogate kidney endpoint, such as estimated glomerular filtration rate (eGFR) slope maybe attractive to assess the kidney in cardiovascular trials, especially heart failure (HF).<br />Recent Findings: eGFR slope can generate informative results in a shorter follow-up period, has decreased risk of type-2 error, and is less sensitive to eGFR shifts compared with other surrogate kidney endpoints (eGFR decline≥40% or doubling creatinine). However, eGFR slope has its limitations with acute effects, heterogeneity in slope calculation/reporting, and deviations from linearity. eGFR slope is a kidney endpoint which may be well-suited for HF trials. Cross-collaborated guideline recommendations are needed to optimize the use of eGFR slope as a kidney endpoint in patients with HF.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Details
- Language :
- English
- ISSN :
- 1546-9549
- Volume :
- 21
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Current heart failure reports
- Publication Type :
- Academic Journal
- Accession number :
- 38795231
- Full Text :
- https://doi.org/10.1007/s11897-024-00668-8